Trice Medical Achieves CE Mark and Health Canada Approval for Mi-Eye 2

Trice Medical announced the completion of its first successful case performed in the United Kingdom, after receiving CE Mark of approval in Europe for the mi-eye 2, as well as entry into Health Canada.
 
The case was performed by Tony Andrade, M.D., a consultant orthopedic surgeon at Circle Reading Hospital. “This is a fantastic opportunity to be able to show patients what’s going on inside their joints and talk them through it live as you see the pathology. This is something that’s been needed for a long time to aid patient’s understanding of their condition. It’s useful not just for diagnostic purposes, but it allows for the delivery of injections into the appropriate targeted area.” said Andrade.
 
The early success of Trice Medical’s mi-eye 2, which was launched in the United States in 2017, has captured the attention of medical professionals who are embracing the technology as a new diagnostic modality. After the first year of commercial launch, the mi-eye is currently being used by over 200 institutions throughout the United States. The disposable needle embedded with a wide-angle camera lens enables physicians to diagnose joint injuries right in their clinic, and provide their patients with immediate answers to the cause of their pain.
 
“Truly disruptive technology always provides value by enhancing care and lowering cost. This approach to diagnosis is such a proposition,” stated Jon J.P. Warner, M.D., chief, MGH Shoulder Service, and professor of orthopedic surgery at Harvard Medical School.
 
Additionally, Anthony Miniaci, M.D., of the Cleveland Clinic Canada, has completed the first cases performed by a surgeon in Toronto, Ontario. The advent of this technology in the Canadian market has the potential to provide patients with a dramatic amount of time saved in their overall continuum of care per injury.
 
“Trice is proud and excited to be commercializing the mi-eye 2 into Europe and Canada. MRI and Ultrasound will always be good options for patients with sports injuries. We are thrilled to add disposable in-clinic arthroscopy to the list of available tools physicians have to be able to assess joint injuries. In many countries, the mi-eye 2 has a chance to save weeks to months of the treatment pathway to surgery and provide a dynamic image of the joint. The is truly an example of innovation in the new world of value-based medicine,” said Mark Foster, chief commercialization officer and vice president of worldwide sales at Trice Medical.

“I had an operation back in December but was still having some knee problems. I didn’t want to go through another general anesthetic operation so Mr. Andrade recommended the mi-eye procedure would be a good option…,” the United Kingdom-based patient said. “The experience overall was fantastic, and I didn’t feel any pulling, tugging or pressure. Mr. Andrade has now identified what we need to do next for my treatment. I would definitely recommend it to others.”
 
Trice Medical’s mi-eye 2 is a handheld single-use, disposable direct visualization tool. The mi-eye 2 was specifically designed for use in the clinic setting, consisting of a single stick percutaneous, and self-blunting design which deploys an integrated camera and a light source. The procedure is performed with local anesthetic and provides patients with an alternative to traditional diagnostic modalities, such as time-consuming and often inaccurate MRIs. The mi-eye is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination and visualization of an interior cavity of the body through either a natural or surgical opening. mi-eye 2 is available for prescription use only.
 
Trice Medical was founded to fundamentally improve orthopedic diagnostics for the patient, and the physician providing instant answers. Trice Medical has helped pioneer fully integrated camera-enabled technology with the mi-eye 2, a product that provides a clinical solution optimized for the physician’s office. Trice Medical’s mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system. The company is based in Malvern, Pa.